This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
*Hemophilia FIX Market Assessment. Third-Party Market Research.
†Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials.
‡Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
§The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.
“On IDELVION, I can enjoy what I’m doing. I don’t have to worry as much about the impact of hemophilia B.”
IDELVION offers a wide variety of resources
to help people with hemophilia B.
Call
1-800-676-4266
For one-on-one support
with a care coordinator
